Ontology highlight
ABSTRACT:
PROVIDER: PRJNA819222 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Other | ||||
| SRR18459482.fastq.gz | Fastqsanger.gz | |||
| SRR18459484.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 3 of 3 |
Similar Datasets
Project description:TransplantLines is designed as a single-center, prospective cohort study and biobank including all different types of solid organ transplant recipients as well as living organ donors. In the TransplantLines gut microbiome study the gut microbiome of solid organ transplant recipients is characterized and linked to clinical phenotypes. This batch contains the cross-sectional data from liver transplant recipients and longitudinal data from renal and liver transplant recipients.
| EGAS00001006258 | EGA
Project description:TransplantLines is designed as a single-center, prospective cohort study and biobank including all different types of solid organ transplant recipients as well as living organ donors. In the TransplantLines gut microbiome study the gut microbiome of solid organ transplant recipients is characterized and linked to clinical phenotypes. This batch contains the cross-sectional data from renal transplant recipients is.
| EGAS00001006257 | EGA
Project description:Tacrolimus (TAC) is an immunosuppressant widely used in kidney transplantation. TAC displays considerable inter-individual variability in pharmacokinetics (PK). Genetic and clinical factors play important roles in TAC PK. To define genetic factors associated with tacrolimus blood trough concentration, we performed a genome-wide association study of renal transplant samples from 251 Chinese renal transplant recipients. We identified 23 single nucleotide polymorphisms (SNPs) related to TAC PK variability. All 23 genome-wide significant SNPs (p<5E-8) were located on chromosome 7, including rs776746. These findings suggest that these SNPs may be associated with the unexlained TAC PK variability in renal transplant recipients and require further investigation.
2022-02-24 | GSE196772 | GEO
Project description:In stable renal transplant recipients with hyperparathyroidism, the vitamin D agonist paricalcitol reduces the level of proteinuria. Animal studies have indicated possible anti-fibrotic and anti-inflammatory effects of paricalcitol. We hypothesised that early introduction of paricalcitol in de novo renal transplant recipients would reduce proteinuria and counteract development of fibrosis in the allograft.
2017-09-01 | GSE83486 | GEO
Project description:<p>In this study, we investigated the role of the gut microbiota on the development of complications in kidney transplant recipients. We collected serial fecal specimens from 168 kidney transplant recipients within the first 3 months after transplantation. We performed 16S rRNA gene sequencing of the V4-V5 hypervariable region and examined whether the relative gut abundance of pathogenic bacteria was associated with future development of complications like bacteriuria and urinary tract infections. In a subset of samples, we performed metagenomic sequencing of stool and urine supernatant specimens to determine strain level analysis. </p>
| phs001879 | dbGaP
Project description:In stable renal transplant recipients with hyperparathyroidism, the vitamin D agonist paricalcitol reduces the level of proteinuria. Animal studies have indicated possible anti-fibrotic and anti-inflammatory effects of paricalcitol. We hypothesised that early introduction of paricalcitol in de novo renal transplant recipients would reduce proteinuria and counteract development of fibrosis in the allograft. A single centre, prospective, randomized, open label trial investigating the additional effect of paricalcitol 2ug/day to standard care was performed. Participants were included 8 weeks after engraftment irrespective of PTH-level and followed for 44 weeks. Microarray analyses were performed in kidney biopsies at study end for the investigation of potential effects on gene expression profile. This dataset is part of the TransQST collection.
2017-09-01 | E-GEOD-83486 | biostudies-arrayexpress
Project description:Effect of Mycophenolic Acid on renal transplant recipients
| PRJNA112285 | ENA
Project description:Monocytic HLA-DR density in renal transplant recipients
| PRJNA843961 | ENA
Project description:Cohort study of 137 renal transplant recipients and 29 non-immunosuppressed controls, looking at clinical influences upon monocytic HLA-DR density (mHLA-DRd) and associated clinical outcomes (namely, malignancy development)
2022-06-02 | GSE205122 | GEO
Project description:<p>Background: Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disorder characterized by progressive renal cyst formation, often leading to end-stage kidney disease (ESKD). While urinary metabolomics in ADPKD has been extensively studied, the composition of renal cyst fluid, particularly in advanced stages, remains largely unexplored.</p><p>Methods: We conducted a comprehensive metabolomic analysis of renal cyst fluid from 26 ADPKD patients (20 on dialysis, six with kidney transplants) using ¹H-NMR spectroscopy and mass spectrometry. Cysts were clustered based on NMR measurements, and differences were analyzed across groups defined by renal function status, cyst volume and cyst fluid sodium concentrations.</p><p>Results: Metabolomic profiling revealed significant differences between cyst fluid compositions from dialysis patients and transplant recipients. Transplant recipients exhibited elevated levels of proteinogenic amino acids such as leucine, isoleucine, valine and alanine, with concentrations 2-3-fold higher than physiological serum levels. Conversely, dialysis patients had higher levels of myoinositol (334 ± 101 µM vs 108 ± 74 µM in transplant recipients), creatinine, sucrose, τ-methylhistidine, trigonelline and sarcosine. Despite intra- and interindividual variability, cyst fluid from the same patient displayed significant homogeneity. Interestingly, metabolomic profiles were not altered by cyst size.</p><p>Conclusion: This first systematic metabolomic analysis of renal cyst fluid in advanced ADPKD reveals distinct metabolic signatures linked to renal function, offering new insights into cystogenesis and disease progression. Although the data were obtained from advanced-stage disease, they provide novel insights into the pathophysiology of ADPKD and highlight the potential of renal cyst fluid metabolomics for identifying biomarkers and therapeutic targets.</p>
2025-07-07 | MTBLS12372 | MetaboLights